Johnson & Johnson to Pay $5.5bn Settlement in Talc Cancer Lawsuit

Johnson & Johnson has agreed to pay an estimated $5.5 billion to settle tens of thousands of lawsuits alleging its talc-based products caused ovarian cancer in women who used them as babies. The settlement acknowledges that the company’s products may have been tainted with asbestos, a known carcinogen, and that it had a responsibility to protect those who trusted its brands.

The agreement comes after a decade-long legal battle during which Johnson & Johnson won some trials but lost others, including a multibillion-dollar verdict in favor of 22 women who claimed baby powder caused their ovarian cancer. The company repeatedly denied that its talc products contained asbestos and caused cancer, despite expert testimony to the contrary.

Johnson & Johnson stopped selling its talc-based baby powder in the US in 2020 and switched to a cornstarch product. However, litigation resumed in March 2025 after the company’s failed attempt to settle cases through bankruptcy. The current agreement applies only to existing claims and does not address future lawsuits.

The exclusion of future claims made more money available to current plaintiffs than previous proposals did. Chris Seeger, a lawyer representing about 2,500 clients with talc claims, said, “We got a fair settlement, and our clients are going to be happy with it.” However, the company’s decision to settle raises questions about its commitment to product safety when profits were at stake.

Historically, Johnson & Johnson has been known for its commitment to quality and safety. But this case highlights concerns that the company may have prioritized profits over consumer well-being. The fact that J&J continued to sell its talc-based products despite mounting evidence of asbestos contamination is a serious issue. Moreover, the company’s efforts to disqualify plaintiffs’ lawyers from the litigation and cast doubt on individual plaintiffs’ ability to prove their cases in court suggest a concerted effort to avoid accountability.

Regulators and lawmakers will need to scrutinize J&J’s actions to ensure that similar cases do not occur in the future. The fact that Johnson & Johnson ultimately chose to settle these claims rather than continuing to fight them suggests that there was growing recognition within the company that its products may have caused harm.

The settlement could have significant implications for public health policy. If J&J’s actions are found to be reckless or negligent, it could pave the way for more stringent regulations on product safety and liability. This could also lead to a reevaluation of how companies handle product recalls and settlements in cases where consumers may have been harmed.

The legacy of talc-based products will likely take years to unravel, but this settlement marks an important step towards accountability and transparency. As we move forward, it is crucial that regulators and lawmakers prioritize the health and safety of consumers above corporate interests. Only then can we ensure that companies like Johnson & Johnson put their users’ well-being ahead of profits.

The swift resolution of these cases also raises questions about the role of bankruptcy in product liability claims. While J&J’s attempts to settle cases through bankruptcy ultimately failed, this strategy has been used by other companies in similar situations. It is time for lawmakers to reconsider the use of bankruptcy as a means of avoiding accountability.

The final payment from Johnson & Johnson is expected to be made in 2028. As we wait for that day to arrive, it’s essential to remember the human cost of this settlement. Thousands of women who used talc-based products as babies are now living with ovarian cancer, a disease that has claimed countless lives. Their stories will serve as a reminder of the importance of product safety and accountability in shaping our public health landscape.

The company still has much to answer for, and it remains to be seen whether this massive payout marks the beginning of a new era of transparency and accountability or simply a necessary cost of doing business in the pharmaceutical industry.